Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies

Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, Rizzo J, Kligys K, Neimark E, Song A, Zambrano J, Mallick M, Cheng E, Armuzzi A (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Journal of Crohns & Colitis Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Pages Range: I126-I127

Conference Proceedings Title: JOURNAL OF CROHNS & COLITIS

DOI: 10.1016/s0016-5085(22)62317-5

Authors with CRIS profile

Raja Atreya Professur für Translationale Immunforschung bei chronisch entzündlichen Darmerkrankungen (Heisenberg-Professur)

Involved external institutions

Cleveland Clinic

United States (USA) (US) Charité - Universitätsmedizin Berlin

Germany (DE) Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Italy (IT) AbbVie Deutschland GmbH & Co. KG

Germany (DE) Western University

Canada (CA) Kyorin University / 杏林大学

Japan (JP) First Pavlov State Medical University of St. Petersburg

Russian Federation (RU)

How to cite

APA:

Atreya, R., Feagan, B., Shchukina, O., Jairath, V., Rieder, F., Hisamatsu, T.,... Armuzzi, A. (2022). Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies. In JOURNAL OF CROHNS & COLITIS (pp. I126-I127). OXFORD: OXFORD UNIV PRESS.

MLA:

Atreya, Raja, et al. "Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies." Proceedings of the JOURNAL OF CROHNS & COLITIS OXFORD: OXFORD UNIV PRESS, 2022. I126-I127.

BibTeX: Download